# Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer

> **NCT04420871** · PHASE1 · COMPLETED · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 48 (actual)

## Conditions studied

- Patient Participation

## Interventions

- **DRUG:** 150 mg of Xeloda®
- **DRUG:** 150 mg of capecitabine

## Key facts

- **NCT ID:** NCT04420871
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-10
- **Primary completion:** 2018-12-28
- **Final completion:** 2019-01-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420871, "Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04420871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*